Lucid Diagnostics Inc.
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
LUCD$0.42+4.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| · · December 31, 2025 · · · December 31, 2024 · | ||||||||
|---|---|---|---|---|---|---|---|---|
| Assets: | | | | | | | | |
| Current assets: | | | | | | | | |
| Cash | | $34,705 | | | $22,358 | | ||
| Accounts receivable | | | 643 | | | | 45 | |
| Inventory | | | 353 | | | | 341 | |
| Prepaid expenses, deposits, and other current assets | | | 1,767 | | | | 2,404 | |
| Total current assets | | | 37,468 | | | | 25,148 | |
| Fixed assets, net | | | 809 | | | | 1,062 | |
| Operating lease right-of-use assets | | | 1,806 | | | | 2,637 | |
| Intangible assets, net | | | 315 | | | | 736 | |
| Other assets | | | 47 | | | | 1,132 | |
| Total assets | | $40,445 | | | $30,715 | | ||
| Liabilities, Preferred Stock and Stockholders’ Equity (Deficit) | | | | | | | | |
| Current liabilities: | | | | | | | | |
| Accounts payable | | $970 | | | $1,241 | | ||
| Accrued expenses and other current liabilities | | | 2,719 | | | | 2,829 | |
| Operating lease liabilities, current portion | | | 893 | | | | 854 | |
| Senior Secured Convertible Notes - at fair value | | | 24,000 | | | | 18,600 | |
| Total current liabilities | | | 28,582 | | | | 23,524 | |
| Operating lease liabilities, less current portion | | | 927 | | | | 1,800 | |
| Total liabilities | | | 29,509 | | | | 25,324 | |
| Commitments and contingencies (Note 11) | | | | | | | | |
| Stockholders’ Equity: | | | | | | | | |
| Preferred stock, $0.001 par value, 20,000,000 shares authorized; Series B and Series B-1 Convertible Preferred Stock, issued and outstanding 54,274 and 54,419 as of December 31, 2025 and December 31, 2024, respectively | | | 54,274 | | | | 54,419 | |
| Common stock, $0.001 par value, 300,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 131,098,762 and 63,071,950 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | | | 131 | | | | 63 | |
| Additional paid-in capital | | | 230,866 | | | | 154,675 | |
| Accumulated deficit | | | (274,335) | | | (203,766) | ||
| Total Stockholders’ Equity (Deficit) | | | 10,936 | | | | 5,391 | |
| Total Liabilities and Stockholders’ Equity (Deficit) | | $40,445 | | | $30,715 | | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.